Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects

International Immunopharmacology

Volumn 8, Issue 3, 2008, Pages 442-452

  Sundstedt, Anette ^a   Celander, Mona ^a   Hedlund, Gunnar ^a  

^a Active Biotech Research AB   (Sweden)

Author keywords

Cancer; Cytotoxicity; Immunotherapy; Interferon alpha; Tumor targeted superantigens

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C215; PERFORIN; STAPHYLOCOCCUS ENTEROTOXIN A; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; EX VIVO STUDY; FEMALE; IMMUNOMODULATION; KIDNEY CARCINOMA; LUNG TUMOR; MELANOMA; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR CELL; TUMOR MODEL;

ANIMALS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; ENTEROTOXINS; FEMALE; IMMUNOGLOBULIN FAB FRAGMENTS; INTERFERON TYPE II; INTERFERON-ALPHA; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SUPERANTIGENS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 38949121964     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.11.006     Document Type: Article

References (50)

1. Dohlsten M., Abrahmsen L., Bjork P., Lando P.A., Hedlund G., Forsberg G., et al. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci U S A 91 (1994) 8945-8949
2. Lando P.A., Dohlsten M., Ohlsson L., and Kalland T. Tumor-reactive superantigens suppress tumor growth in humanized SCID mice. Int J Cancer 62 (1995) 466-471
3. Forsberg G., Ohlsson L., Brodin T., Bjork P., Lando P.A., Shaw D., et al. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer 85 (2001) 129-136
4. Shaw D.M., Connolly N.B., Patel P.M., Kilany S., Hedlund G., Nordle O., et al. A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer 96 (2007) 567-574
5. Kappler J., Kotzin B., Herron L., Gelfand E.W., Bigler R.D., Boylston A., et al. V beta-specific stimulation of human T cells by staphylococcal toxins. Science 244 (1989) 811-813
6. White J., Herman A., Pullen A.M., Kubo R., Kappler J.W., and Marrack P. The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell 56 (1989) 27-35
7. Janeway Jr. C.A., Yagi J., Conrad P.J., Katz M.E., Jones B., Vroegop S., et al. T-cell responses to Mls and to bacterial proteins that mimic its behavior. Immunol Rev 107 (1989) 61-88
8. Dohlsten M., Lando P.A., Hedlund G., Trowsdale J., and Kalland T. Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins. Immunology 71 (1990) 96-100
9. Dohlsten M., Sundstedt A., Bjorklund M., Hedlund G., and Kalland T. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer 54 (1993) 482-488
10. Hedlund G., Dohlsten M., Lando P.A., and Kalland T. Staphylococcal enterotoxins direct and trigger CTL killing of autologous HLA-DR+ mononuclear leukocytes and freshly prepared leukemia cells. Cell Immunol 129 (1990) 426-434
11. Rosendahl A., Hansson J., Sundstedt A., Kalland T., and Dohlsten M. Immune response during tumor therapy with antibody-superantigen fusion proteins. Int J Cancer 68 (1996) 109-113
12. Litton M.J., Dohlsten M., Rosendahl A., Ohlsson L., Sogaard M., Andersson J., et al. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens. Br J Cancer 81 (1999) 359-366
13. Rosendahl A., Kristensson K., Hansson J., Riesbeck K., Kalland T., and Dohlsten M. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens. J Immunol 160 (1998) 5309-5313
14. Dohlsten M., Hansson J., Ohlsson L., Litton M., and Kalland T. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci U S A 92 (1995) 9791-9795
15. Litton M.J., Dohlsten M., Hansson J., Rosendahl A., Ohlsson L., Kalland T., et al. Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses. Am J Pathol 150 (1997) 1607-1618
16. Gutterman J.U. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A 91 (1994) 1198-1205
17. Pfeffer L.M., Dinarello C.A., Herberman R.B., Williams B.R., Borden E.C., Bordens R., et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58 (1998) 2489-2499
18. Belardelli F., and Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 17 (1996) 369-372
19. Santini S.M., Lapenta C., Logozzi M., Parlato S., Spada M., Di Pucchio T., et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191 (2000) 1777-1788
20. Luft T., Pang K.C., Thomas E., Hertzog P., Hart D.N., Trapani J., et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161 (1998) 1947-1953
21. Muller U., Steinhoff U., Reis L., Hemmi S., Pavlovic J., Zinkernagel R., et al. Functional role of type I and type II interferons in antiviral defense. Science 264 (1994) 1918-1921
22. Tough D.F., Borrow P., and Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272 (1996) 1947-1950
23. von Hoegen P., Zawatzky R., and Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta. Cell Immunol 126 (1990) 80-90
24. Ferrantini M., Giovarelli M., Modesti A., Musiani P., Modica A., Venditti M., et al. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. J Immunol 153 (1994) 4604-4615
25. Dohlsten M., Hedlund G., Akerblom E., Lando P.A., and Kalland T. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci U S A 88 (1991) 9287-9291
26. Abrahmsen L., Dohlsten M., Segren S., Bjork P., Jonsson E., and Kalland T. Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J 14 (1995) 2978-2986
27. Badgwell B., Lesinski G.B., Magro C., Abood G., Skaf A., and Carson III W. The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line. J Surg Res 116 (2004) 129-136
28. Hiroishi K., Tuting T., and Lotze M.T. IFN-{alpha}-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol 164 (2000) 567-572
29. Sundstedt A., Dohlsten M., Hedlund G., Hoiden I., Bjorklund M., and Kalland T. Superantigens anergize cytokine production but not cytotoxicity in vivo. Immunology 82 (1994) 117-125
30. Litton M.J., Dohlsten M., Lando P.A., Kalland T., Ohlsson L., Andersson J., et al. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol 26 (1996) 1-9
31. Sundstedt A., Grundstrom S., and Dohlsten M. T cell- and perforin-dependent depletion of B cells in vivo by staphylococcal enterotoxin A. Immunology 95 (1998) 76-82
32. Nathan P.D., and Eisen T.G. The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol 3 (2002) 89-96
33. Kaido T., Bandu M.T., Maury C., Ferrantini M., Belardelli F., and Gresser I. IFN-alpha 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int J Cancer 60 (1995) 221-229
34. Motzer R.J., Mazumdar M., Bacik J., Russo P., Berg W.J., and Metz E.M. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18 (2000) 1928-1935
35. Belardelli F., Ferrantini M., Proietti E., and Kirkwood J.M. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13 (2002) 119-134
36. Kagi D., Vignaux F., Ledermann B., Burki K., Depraetere V., Nagata S., et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265 (1994) 528-530
37. Masson D., and Tschopp J. Isolation of a lytic, pore-forming protein (perforin) from cytolytic T-lymphocytes. J Biol Chem 260 (1985) 9069-9072
38. Heusel J.W., Wesselschmidt R.L., Shresta S., Russell J.H., and Ley T.J. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76 (1994) 977-987
39. Hedlund G., Dohlsten M., Petersson C., and Kalland T. Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells. Cancer Immunol Immunother 36 (1993) 89-93
40. Mori S., Jewett A., Cavalcanti M., Murakami-Mori K., Nakamura S., and Bonavida B. Differential regulation of human NK cell-associated gene expression following activation by IL-2, IFN-alpha and PMA/ionomycin. Int J Oncol 12 (1998) 1165-1170
41. Balian A., Naveau S., Zou W., Durand-Gasselin I., Bouchet L., Foussat A., et al. Pretreatment expression of the perforin gene by circulating CD8(+) T lymphocytes predicts biochemical response to interferon-alpha in patients with chronic hepatitis C. Eur Cytokine Netw 11 (2000) 177-184
42. MacDonald H.R., Baschieri S., and Lees R.K. Clonal expansion precedes anergy and death of V beta 8+ peripheral T cells responding to staphylococcal enterotoxin B in vivo. Eur J Immunol 21 (1991) 1963-1966
43. Kearney E.R., Pape K.A., Loh D.Y., and Jenkins M.K. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1 (1994) 327-339
44. Marrack P., Kappler J., and Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 189 (1999) 521-530
45. Akbar A.N., Borthwick N.J., Wickremasinghe R.G., Panayoitidis P., Pilling D., Bofill M., et al. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur J Immunol 26 (1996) 294-299
46. Vella A.T., Dow S., Potter T.A., Kappler J., and Marrack P. Cytokine-induced survival of activated T cells in vitro and in vivo. Proc Natl Acad Sci U S A 95 (1998) 3810-3815
47. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., and Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14 (2001) 461-470
48. Belardelli F., Ferrantini M., Santini S.M., Baccarini S., Proietti E., Colombo M.P., et al. The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice. Cancer Res 58 (1998) 5795-5802
49. Prell R.A., Li B., Lin J.M., VanRoey M., and Jooss K. Administration of IFN-{alpha} enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine. Cancer Res 65 (2005) 2449-2456
50. Di Pucchio T., Pilla L., Capone I., Ferrantini M., Montefiore E., Urbani F., et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-{alpha} results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors. Cancer Res 66 (2006) 4943-4951